Q-omics provides the consensus-scored TIMM21 profile across patient tissues and cancer cell-line models. TIMM21 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TIMM21 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TIMM21 protein abundance shows 34,766 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, THCA, and LSCC as cancer lineages where TIMM21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIMM21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIMM21 survival associations across molecular data types. TIMM21 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIMM21 RNA expression–survival associations across cancer types. High TIMM21 expression shows unfavorable associations in LIHC, ACC and UVM, but favorable associations in KIRP, LUSC and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TIMM21 RNA expression.
This table summarizes TIMM21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TIMM21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIMM21 shows lower tumor expression in THCA and BLCA and higher tumor expression in LIHC, LUSC, LUAD and CHOL. The THCA box plot shows higher TIMM21 RNA expression in normal versus tumor tissue (log2 FC = −1.156, t-test p < 0.001).
This table shows molecular features associated with TIMM21 in patient tissues and cancer cell lines. In patient samples, TIMM21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TIMM21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
